布地奈德、特布他林及异丙托溴铵三联吸入治疗COPD患者的效果及对炎性介质的影响(1)
【摘要】 目的：探討布地奈德、特布他林及异丙托溴铵三联吸入治疗急性加重期慢性阻塞性肺疾病(COPD)患者的效果及对炎性介质白介素-6(IL-6)、白介素-8(IL-8)、肿瘤坏死因子α(TNF-α)的影响。方法：选取2012年10月-2019年5月本院内科收治的急性加重期COPD患者68例为研究对象，按住院号单双数分为观察组和对照组，各34例。两组均给予常规治疗，在常规治疗基础上对照组给予硫酸特布他林治疗，观察组给予硫酸特布他林、异丙托溴铵及布地奈德联合治疗。观察比较两组治疗前后血清炎症因子(TNF-α、IL-8、IL-6)的变化及临床疗效、不良反应发生情况。结果：观察组患者的总有效率为94.1%，明显高于对照组的76.5%，差异有统计学意义(P<0.05)。治疗期间两组患者均没有发生严重的不良反应。治疗后，两组患者FEV1、FVC、PaO2、PaCO2均较治疗前有明显改善(P<0.05)，且观察组上述指标的改善程度均明显优于对照组(P<0.05)。治疗后，两组患者血清TNF-α、IL-8、IL-6表达水平均较治疗前明显降低(P<0.05)，且观察组上述指标的降低幅度均明显大于对照组(P<0.05)。结论：硫酸特布他林、异丙托溴铵溶液和布地奈德三联雾化治疗方案治疗COPD临床效果显著，可明显改善患者肺功能和血气分析的各项指标，并能够有效减轻患者炎症反应，利于患者康复。
【关键词】 慢性阻塞性肺疾病 TNF-α IL-8 IL-6 肺功能
[Abstract] Objective： To investigate the efficacy of Budesonide， Terbutaline and Ipratropium Bromide inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) and the effects on inflammatory mediators IL-6， IL-8 and TNF-α. Method： A total of 68 cases with acute aggravating period of COPD admitted to our hospital from October 2012 to May 2019 were selected as the research objects， the patients were divided into observation group and control group according to the number of admission， 34 cases in each group. Both groups were given conventional treatment， the control group was given Terbutaline Sulfate on the basis of conventional treatment， and the observation group was given Terbutaline Sulfate， Ipratropium Bromide and Budesonide combined treatment. Changes of serum inflammatory factors (TNF-α， IL-8， IL-6) before and after treatment， clinical efficacy and adverse reactions were observed and compared in the two groups. Result： The total effective rate of observation group was 94.1%， significantly higher than 76.5% of the control group， the difference was statistically significant (P<0.05). No serious adverse reactions occurred during treatment in both groups. After treatment， FEV1， FVC， PaO2 and PaCO2 in both groups were significantly improved compared with those before treatment (P<0.05)， and the improvement degree of these indicators in the observation group were significantly better than those in the control group (P<0.05). After treatment， the expression levels of serum TNF-α， IL-8 and IL-6 in the two groups were significantly lower than those of before treatment (P<0.05)， and the decrease of these indicators in the observation group were significantly greater than those in the control group (P<0.05). Conclusion： Treatment of COPD with Terbutaline Sulfate， Ipratropium Bromide Solution and Budesonide Triple atomization therapy has significant clinical effects， significantly improving the pulmonary function and blood gas indexes of patients， and effectively reducing the inflammatory response of patients， which is conducive to the recovery of patients., 百拇医药(钟孜燕 刘哲 李启恭 黄世宣)
【关键词】 慢性阻塞性肺疾病 TNF-α IL-8 IL-6 肺功能
[Abstract] Objective： To investigate the efficacy of Budesonide， Terbutaline and Ipratropium Bromide inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) and the effects on inflammatory mediators IL-6， IL-8 and TNF-α. Method： A total of 68 cases with acute aggravating period of COPD admitted to our hospital from October 2012 to May 2019 were selected as the research objects， the patients were divided into observation group and control group according to the number of admission， 34 cases in each group. Both groups were given conventional treatment， the control group was given Terbutaline Sulfate on the basis of conventional treatment， and the observation group was given Terbutaline Sulfate， Ipratropium Bromide and Budesonide combined treatment. Changes of serum inflammatory factors (TNF-α， IL-8， IL-6) before and after treatment， clinical efficacy and adverse reactions were observed and compared in the two groups. Result： The total effective rate of observation group was 94.1%， significantly higher than 76.5% of the control group， the difference was statistically significant (P<0.05). No serious adverse reactions occurred during treatment in both groups. After treatment， FEV1， FVC， PaO2 and PaCO2 in both groups were significantly improved compared with those before treatment (P<0.05)， and the improvement degree of these indicators in the observation group were significantly better than those in the control group (P<0.05). After treatment， the expression levels of serum TNF-α， IL-8 and IL-6 in the two groups were significantly lower than those of before treatment (P<0.05)， and the decrease of these indicators in the observation group were significantly greater than those in the control group (P<0.05). Conclusion： Treatment of COPD with Terbutaline Sulfate， Ipratropium Bromide Solution and Budesonide Triple atomization therapy has significant clinical effects， significantly improving the pulmonary function and blood gas indexes of patients， and effectively reducing the inflammatory response of patients， which is conducive to the recovery of patients., 百拇医药(钟孜燕 刘哲 李启恭 黄世宣)